LBLaura Berliocchi

Laura Berliocchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Berliocchi has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting lipid homeostasis for preventive intervention in brain aging and Alzheimer’s disease

    by Laura Berliocchi, Marcus O. W. Grimm, Tobias Hartmann, Luca Tirinato, Kristine Freude, Emanuela Grillo, Daniele Bano, Lene Juel Rasmussen

    Background: Lipids are essential for brain structure and function, contributing to membrane integrity, synaptic activity, signal transduction, and energy metabolism. Converging evidence from human genetics, epidemiology, lipidomics, and neuroimaging indicates that disrupted lipid homeostasis is an early and biologically relevant feature of brain aging and Alzheimer’s disease (AD), rather than a mere downstream consequence of neurodegeneration. In particular, abnormalities in cholesterol transport, sphingolipid metabolism, phospholipid turnover, and apolipoprotein-mediated lipid trafficking have been associated with cognitive decline, structural brain changes, and AD risk. Main body: This narrative review synthesizes evidence from selected major human cohort, biomarker, neuroimaging, and clinical intervention studies linking lipid homeostasis to brain aging and AD, with a particular focus on blood, cerebrospinal fluid (CSF), and brain imaging biomarkers, as well as preventive interventions targeting lipid metabolism. Across human cohorts, the most consistent findings include altered ceramide and sphingomyelin metabolism, changes in phosphatidylcholine and membrane phospholipid turnover, and impaired cholesterol transport involving APOE and ATP-binding cassette transporters such as ABCA1 and ABCA7. Although direct evidence for lipid droplets (LDs) involvement in humans remains limited, indirect clinical and translational findings support their emerging relevance in neuron-glia metabolic crosstalk, cellular stress responses, and neuroinflammation. Importantly, many lipid-related pathways appear modifiable. Lifestyle factors such as diet, physical activity, and metabolic health strongly influence lipid homeostasis and overlap with established modifiable dementia risk factors. Clinical studies of lipid-targeted interventions, including omega-3 fatty acids, ketogenic strategies, multinutrient formulations, statins, plasmalogens, and pharmacological approaches targeting cholesterol turnover or ApoE-related pathways, suggest that efficacy is heterogeneous, context-dependent, and most likely to emerge when interventions are implemented early, before advanced neurodegeneration is established. Conclusions: Current human evidence highlights lipid homeostasis as a measurable and partly tractable interface between systemic metabolism, brain aging, and AD pathogenesis. Lipid dysregulation may therefore provide clinically relevant biomarkers for early risk stratification and monitoring of disease progression, as well as a mechanistic framework for prevention-oriented interventions. Preserving or restoring lipid balance may represent a promising strategy to promote brain health and reduce dementia risk across aging trajectories.

  • Open Access

    Interactions between mitochondrial dysfunction and other hallmarks of aging: Paving a path toward interventions that promote healthy old age

    by Yuan Li, Laura Berliocchi, Zhiquan Li, Lene Juel Rasmussen

    Current research on human aging has largely been guided by the milestone paper “hallmarks of aging,” which were first proposed in the seminal 2013 paper by Lopez‐Otin et al. Most studies have focused on one aging hallmark at a time, asking whether the underlying molecular perturbations are sufficient to drive the aging process and its associated phenotypes. More recently, researchers have begun to investigate whether aging phenotypes are driven by concurrent perturbations in molecular pathways linked to not one but to multiple hallmarks of aging and whether they present different patterns in organs and systems over time. Indeed, preliminary results suggest that more complex interactions between aging hallmarks must be considered and addressed, if we are to develop interventions that successfully promote healthy aging and/or delay aging‐associated dysfunction and diseases. Here, we summarize some of the latest work and views on the interplay between hallmarks of aging, with a specific focus on mitochondrial dysfunction. Indeed, this represents a significant example of the complex crosstalk between hallmarks of aging and of the effects that an intervention targeted to a specific hallmark may have on the others. A better knowledge of these interconnections, of their cause‐effect relationships, of their spatial and temporal sequence, will be very beneficial for the whole aging research field and for the identification of effective interventions in promoting healthy old age.


  • Open Access

    Pooled analysis of frontal lobe transcriptomic data identifies key mitophagy gene changes in Alzheimer's disease brain

    by Taoyu Mei, Yuan Li, Anna Orduña Dolado, Zhiquan Li, Robin Andersson, Laura Berliocchi, Lene Juel Rasmussen

    Background: The growing prevalence of Alzheimer's disease (AD) is becoming a global health challenge without effective treatments. Defective mitochondrial function and mitophagy have recently been suggested as etiological factors in AD, in association with abnormalities in components of the autophagic machinery like lysosomes and phagosomes. Several large transcriptomic studies have been performed on different brain regions from AD and healthy patients, and their data represent a vast source of important information that can be utilized to understand this condition. However, large integration analyses of these publicly available data, such as AD RNA-Seq data, are still missing. In addition, large-scale focused analysis on mitophagy, which seems to be relevant for the aetiology of the disease, has not yet been performed.Methods: In this study, publicly available raw RNA-Seq data generated from healthy control and sporadic AD post-mortem human samples of the brain frontal lobe were collected and integrated. Sex-specific differential expression analysis was performed on the combined data set after batch effect correction. From the resulting set of differentially expressed genes, candidate mitophagy-related genes were identified based on their known functional roles in mitophagy, the lysosome, or the phagosome, followed by Protein-Protein Interaction (PPI) and microRNA-mRNA network analysis. The expression changes of candidate genes were further validated in human skin fibroblast and induced pluripotent stem cells (iPSCs)-derived cortical neurons from AD patients and matching healthy controls.Results: From a large dataset (AD: 589; control: 246) based on three different datasets (i.e., ROSMAP, MSBB, & GSE110731), we identified 299 candidate mitophagy-related differentially expressed genes (DEG) in sporadic AD patients (male: 195, female: 188). Among these, the AAA ATPase VCP, the GTPase ARF1, the autophagic vesicle forming protein GABARAPL1 and the cytoskeleton protein actin beta ACTB were selected based on network degrees and existing literature. Changes in their expression were further validated in AD-relevant human in vitro models, which confirmed their down-regulation in AD conditions.Conclusion: Through the joint analysis of multiple publicly available data sets, we identify four differentially expressed key mitophagy-related genes potentially relevant for the pathogenesis of sporadic AD. Changes in expression of these four genes were validated using two AD-relevant human in vitro models, primary human fibroblasts and iPSC-derived neurons. Our results provide foundation for further investigation of these genes as potential biomarkers or disease-modifying pharmacological targets.


  • Effects of the autophagy modulators d-limonene and chloroquine on vimentin levels in SH-SY5Y cells

    by Debora Gentile, Laura Berliocchi, Rossella Russo, Giacinto Bagetta, Maria Tiziana Corasaniti


  • Inhibition of monoacylglycerol lipase: Another signalling pathway for potential therapeutic targets in migraine?

    by Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni, Laura Berliocchi, Daniele Piomelli, Cristina Tassorelli

    Background: Drugs that modulate endocannabinoid signalling are effective in reducing nociception in animal models of pain and may be of value in the treatment of migraine. Methods: We investigated the anti-nociceptive effects of inhibition of monoacylglycerol lipase (MGL), a key enzyme in the hydrolysis of the 2-arachidonoylglycerol, in a rat model of migraine based on nitroglycerin (NTG) administration. We evaluated c-fos expression in specific brain areas and nociceptive behavior in trigeminal and extra-trigeminal body areas. Results: URB602, a reversible MGL inhibitor, did not show any analgesic effect in the tail flick test, but it inhibited NTG-induced hyperalgesia in both the tail flick test and the formalin test applied to the hind paw or to the orofacial area. Quite unexpectedly, URB602 potentiated formalin-induced hyperalgesia in the trigeminal area when used alone. The latter result was also confirmed using a structurally distinct, irreversible MGL inhibitor, JZL184. URB602 did not induce neuronal activation in the area of interest, but significantly reduced the NTG-induced neuronal activation in the ventrolateral column of the periaqueductal grey and the nucleus trigeminalis caudalis. Conclusions: These findings support the hypothesis that modulation of the endocannabinoid system may be a valuable approach for the treatment of migraine. The topographically segregated effect of MGL inhibition in trigeminal/extra-trigeminal areas calls for further mechanistic research.


  • Open Access

    Spinal Autophagy is Differently Modulated in Distinct Mouse Models of Neuropathic Pain

    by Laura Berliocchi, Maria Maiarù, Giuseppe Pasquale Varano, Rossella Russo, Maria Tiziana Corasaniti, Giacinto Bagetta, Cristina Tassorelli

    Background: Autophagy is a homeostatic degradative process essential for basal turnover of long-lived proteins and organelles as well as for removal of dysfunctional cellular components. Dysregulation of the autophagic machinery has been recently associated to several conditions including neurodegenerative diseases and cancer, but only very few studies have investigated its role in pain processing. Results: We previously described autophagy impairment at the spinal cord in the experimental model of neuropathic pain induced by spinal nerve ligation (SNL). In this study, we characterized the main autophagic markers in two other common experimental models of neuropathic pain, the chronic constriction injury (CCI) and the spared nerve injury (SNI). The different modulation of LC3-I, Beclin 1 and p62 suggested that autophagy is differentially affected in the spinal dorsal horn depending on the type of peripheral injury. Confocal analysis of p62 distribution in the spinal dorsal horn indicated its presence mainly in NeuN-positive cell bodies and occasionally in glial processes, thus suggesting a predominant expression in the neuronal compartment. Finally, we investigated the consequences of autophagy impairment on pain behaviour by using the autophagy blocker cloroquine. Intrathecal chloroquine injection in naïve mice induced spinal accumulation of LC3 and p62 paralleled by significant mechanical hypersensitivity thus confirming the block in autophagosome clearance and suggesting the participation of the autophagic process in spinal mechanisms of pain processing. Altogether, our data indicate that spinal autophagy is differentially altered in different experimental pain models of neuropathic pain and that this process may be relevant for pain control.


  • Open Access

    Role of D-Limonene in Autophagy Induced by Bergamot Essential Oil in SH-SY5Y Neuroblastoma Cells

    by Rossella Russo, Maria Gilda Valentina Cassiano, Antonella Ciociaro, Annagrazia Adornetto, Giuseppe Pasquale Varano, Carlotta Chiappini, Laura Berliocchi, Cristina Tassorelli, Giacinto Bagetta, Maria Tiziana Corasaniti

    Bergamot (Citrus bergamia, Risso et Poiteau) essential oil (BEO) is a well characterized, widely used plant extract. BEO exerts anxiolytic, analgesic and neuroprotective activities in rodents through mechanisms that are only partly known and need to be further investigated. To gain more insight into the biological effects of this essential oil, we tested the ability of BEO (0.005–0.03%) to modulate autophagic pathways in human SH-SY5Y neuroblastoma cells. BEO-treated cells show increased LC3II levels and appearance of dot-like formations of endogenous LC3 protein that colocalize with the lysosome marker LAMP-1. Autophagic flux assay using bafilomycin A1 and degradation of the specific autophagy substrate p62 confirmed that the observed increase of LC3II levels in BEO-exposed cells is due to autophagy induction rather than to a decreased autophagosomal turnover. Induction of autophagy is an early and not cell-line specific response to BEO. Beside basal autophagy, BEO also enhanced autophagy triggered by serum starvation and rapamycin indicating that the underlying mechanism is mTOR independent. Accordingly, BEO did not affect the phosphorylation of ULK1 (Ser757) and p70S6K (Thr389), two downstream targets of mTOR. Furthermore, induction of autophagy by BEO is beclin-1 independent, occurs in a concentration-dependent manner and is unrelated to the ability of BEO to induce cell death. In order to identify the active constituents responsible for these effects, the two most abundant monoterpenes found in the essential oil, d-limonene (125–750 µM) and linalyl acetate (62.5–375 µM), were individually tested at concentrations comparable to those found in 0.005–0.03% BEO. The same features of stimulated autophagy elicited by BEO were reproduced by d-limonene, which rapidly increases LC3II and reduces p62 levels in a concentration-dependent manner. Linalyl acetate was ineffective in replicating BEO effects; however, it greatly enhanced LC3 lipidation triggered by d-limonene.


  • Implication of limonene and linalyl acetate in cytotoxicity induced by bergamot essential oil in human neuroblastoma cells

    by Rossella Russo, Antonella Ciociaro, Laura Berliocchi, Maria Gilda Valentina Cassiano, Laura Rombolà, Salvatore Ragusa, Giacinto Bagetta, Fabio Blandini, Maria Tiziana Corasaniti


    • 20 April 2013
      • Vol. 27  (4) , 253-5

    New trends in pain research: from basic research to clinical translation.

    by Laura Berliocchi, Maria Maiarù, Damiana Scuteri, Maria Tiziana Corasaniti, Giacinto Bagetta

  • In search of new targets for retinal neuroprotection: is there a role for autophagy?

    by Rossella Russo, Laura Berliocchi, Annagrazia Adornetto, Diana Amantea, Carlo Nucci, Cristina Tassorelli, Luigi Antonio Morrone, Giacinto Bagetta, Maria Tiziana Corasaniti